POSTER: CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
- DOI
- 10.1016/s2152-2650(23)00547-5
- Published
- 2023-09
- Container
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2152-2650-23-00547-5,
title = {POSTER: CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)},
author = {Ehab Atallah and Kejal Jadhav and Teresa Kangappaden and Andrea Damon and Imtiaz Samjoo and David Wei and Devarshi Bhattacharyya},
year = {2023},
journal = {Clinical Lymphoma Myeloma and Leukemia},
doi = {10.1016/s2152-2650(23)00547-5},
url = {https://doi.org/10.1016/s2152-2650(23)00547-5}
}RIS
TY - JOUR TI - POSTER: CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP) AU - Ehab Atallah AU - Kejal Jadhav AU - Teresa Kangappaden AU - Andrea Damon AU - Imtiaz Samjoo AU - David Wei AU - Devarshi Bhattacharyya PY - 2023 JO - Clinical Lymphoma Myeloma and Leukemia DO - 10.1016/s2152-2650(23)00547-5 UR - https://doi.org/10.1016/s2152-2650(23)00547-5 ER -
APA
Atallah, E., Jadhav, K., Kangappaden, T., Damon, A., Samjoo, I., Wei, D., & Bhattacharyya, D. (2023). POSTER: CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/s2152-2650(23)00547-5
Source records
- crossref · retrieved 2026-09-25T20:28:09.862Z